Literature DB >> 12554061

Peripheral-type benzodiazepine receptors in human mononuclear cells of patients affected by osteoarthritis, rheumatoid arthritis or psoriasic arthritis.

Laura Bazzichi1, Laura Betti, Gino Giannaccini, Alessandra Rossi, Antonio Lucacchini.   

Abstract

OBJECTIVES: The objective of this study was to evaluate the kinetic parameters at equilibrium of peripheral benzodiazepine receptors (PBR) in human mononuclear cells from patients affected by osteoarthritis (OA), rheumatoid arthritis (RA) and psoriasic arthritis (PA). DESIGN AND METHODS: Mononuclear cells were obtained from 10 patients with OA, 10 patients with RA and 10 patients with PA. Evaluation of kinetic parameters of PBR was performed using [(3)H]PK 11195, a specific radioligand for this receptor, and compared with 10 healthy controls.
RESULTS: The results show a statistically significant decrease (37.5%, as an absolute percentage) in the maximal number of binding sites (B(max)) of patients with OA, compared with healthy controls; however, the values of the dissociation constant (K(d)) at equilibrium do not show any statistically significant variations.
CONCLUSIONS: These data further confirm the presence of peripheral biochemical alterations in OA. As peripheral benzodiazepine receptors appear to be involved in the immune function, and in the protection of hematopoietic cells against oxygen radical damage, the observed decrease in B(max) might be related to cellular protection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12554061     DOI: 10.1016/s0009-9120(02)00408-3

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  7 in total

1.  Current imaging strategies in rheumatoid arthritis.

Authors:  Merissa N Zeman; Peter Jh Scott
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-03-28

2.  Uptake of inflammatory cell marker [11C]PK11195 into mouse atherosclerotic plaques.

Authors:  Iina Laitinen; Päivi Marjamäki; Kjell Någren; V Jukka O Laine; Ian Wilson; Pia Leppänen; Seppo Ylä-Herttuala; Anne Roivainen; Juhani Knuuti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-19       Impact factor: 9.236

3.  The analgesic effect of midazolam when added to lidocaine for intravenous regional anaesthesia.

Authors:  Parviz Kashefi; Kamran Montazeri; Azim Honarmand; Mohammadreza Safavi; Hashem Mirzaee Hosseini
Journal:  J Res Med Sci       Date:  2011-09       Impact factor: 1.852

4.  The efficacy of different doses of Midazolam added to Lidocaine for upper extremity Bier block on the sensory and motor block characteristics and postoperative pain.

Authors:  Azim Honarmand; Mohammadreza Safavi; Koorosh Nemati; Padideh Oghab
Journal:  J Res Pharm Pract       Date:  2015 Jul-Sep

5.  Pro-inflammatory activation of primary microglia and macrophages increases 18 kDa translocator protein expression in rodents but not humans.

Authors:  David R Owen; Nehal Narayan; Lisa Wells; Luke Healy; Erica Smyth; Eugenii A Rabiner; Dylan Galloway; John B Williams; Joshua Lehr; Harpreet Mandhair; Laura An Peferoen; Peter C Taylor; Sandra Amor; Jack P Antel; Paul M Matthews; Craig S Moore
Journal:  J Cereb Blood Flow Metab       Date:  2017-05-22       Impact factor: 6.200

6.  Inhibitory effect of midazolam on MMP-9, MMP-1 and MMP-13 expression in PMA-stimulated human chondrocytes via recovery of NF-κB signaling.

Authors:  Jen-Jui Wang; Steven Kuan-Hua Huan; Kuo-Hsien Hsieh; Hsiu-Chu Chou; George Hsiao; Thanasekaran Jayakumar; Joen-Rong Sheu
Journal:  Arch Med Sci       Date:  2012-10-08       Impact factor: 3.318

7.  A randomized controlled trial for the effectiveness of intraarticular versus intravenous midazolam on pain after knee arthroscopy.

Authors:  Parvin Sajedi; Mohammad Nemati; Seye Hamid Mosavi; Azim Honarmand; Mohammad Reza Safavi
Journal:  J Res Med Sci       Date:  2014-05       Impact factor: 1.852

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.